New drug combo aims to fight Hard-to-Treat sarcomas
NCT ID NCT04668300
First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This phase II trial tests two immunotherapy drugs, oleclumab and durvalumab, in 75 people with advanced sarcoma (angiosarcoma, dedifferentiated liposarcoma, or osteosarcoma) that has returned, spread, or stopped responding to treatment. The goal is to see if the combination can shrink tumors or slow cancer growth. Participants receive the drugs intravenously, and the study measures response rates and how long the cancer is controlled.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- oleclumab and durvalumab (immunotherapy drugs)
- What this could lead to
- If successful, this could provide a new treatment option for people with certain advanced sarcomas that have not responded to standard therapies.
- What could go wrong
- This is a relatively small, early-phase trial (75 participants) and the drugs may not work for all sarcoma subtypes. Immunotherapy can also cause side effects like inflammation in healthy organs.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for METASTATIC ANGIOSARCOMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
M D Anderson Cancer Center
Houston, Texas, 77030, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Immunotherapy drug sintilimab takes on rare blood vessel cancer
- Glow-in-the-Dark dye could help surgeons find hidden lung cancer in teens
- Desperate hope: single patient gets custom RNA therapy for returning bone cancer
- Targeted drug shows promise for kids with tough cancers
- New hope for kids with Hard-to-Treat cancers: targeted drug shows promise
- New drug targets tough childhood cancers with genetic flaws